Qnostics develops SARS-CoV-2 test controls

Qnostics develops SARS-CoV-2 test controls

Qnostics, a world leading manufacturer of QC solutions for molecular infectious disease testing, has developed a range of products designed to support the validation, verification and performance monitoring...

Supplied by


Qnostics, a world leading manufacturer of QC solutions for molecular infectious disease testing, has developed a range of products designed to support the validation, verification and performance monitoring of molecular assays used in the testing of SARS-CoV-2.

Conveniently combining SARS-CoV-2, Flu A, Flu B and RSV, the new RTX plus control is ideal for use with multiplex assays. A dedicated SARS-CoV-2 control is also available.

Comprising the full SARS CoV-2 genome, the control range is compatible for use with the majority of commercial and in-house assays. Whole pathogen controls are ideal for full-process validation, monitoring the testing process from extraction to amplification and detection, ensuring the ultimate quality assurance in laboratories.

Additionally, the third-party nature of these controls ensures an independent, unbiased assessment of assay performance in-line with ISO 15189 regulatory requirements. Supplied in a liquid easy to use format, minimal preparation is required. A complementary negative control is also available delivering a complete testing package.

For more information, visit: https://www.randox.com/sars-cov-2-molecular-control/


Contact form

Get in touch directly with the above supplier

Your email address will not be communicated to any third party other than the above supplier for the purpose of fulfilling this enquiry. For more information: read our privacy policy.